310 related articles for article (PubMed ID: 17356952)
1. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
Saif MW; Elfiky A; Salem RR
Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
[TBL] [Abstract][Full Text] [Related]
2. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
3. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
Heinzerling JH; Huerta S
Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
[TBL] [Abstract][Full Text] [Related]
5. Managing patients treated with bevacizumab combination therapy.
Gordon MS; Cunningham D
Oncology; 2005; 69 Suppl 3():25-33. PubMed ID: 16301833
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
7. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
Diaz JP; Tew WP; Zivanovic O; Konner J; Sabbatini PJ; dos Santos LA; Abu-Rustum NR; Chi DS; Aghajanian C; Barakat RR
Gynecol Oncol; 2010 Mar; 116(3):335-9. PubMed ID: 20004956
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
Ezzedine S; Bege T; Berdah S; Vitton V; Grimaud JC; Barthet M
Surg Laparosc Endosc Percutan Tech; 2010 Dec; 20(6):e230-2. PubMed ID: 21150409
[TBL] [Abstract][Full Text] [Related]
11. Intricacies of bevacizumab-induced toxicities and their management.
Gressett SM; Shah SR
Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
[TBL] [Abstract][Full Text] [Related]
12. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
August DA; Serrano D; Poplin E
J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
Hurwitz H; Saini S
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
Krämer I; Lipp HP
J Clin Pharm Ther; 2007 Feb; 32(1):1-14. PubMed ID: 17286784
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
[TBL] [Abstract][Full Text] [Related]
17. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.
Saif MW; Longo WL; Israel G
Clin Colorectal Cancer; 2008 Mar; 7(2):144-8. PubMed ID: 18501075
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
Thornton AD; Ravn P; Winslet M; Chester K
Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.
Tol J; Cats A; Mol L; Koopman M; Bos MM; van der Hoeven JJ; Antonini NF; van Krieken JH; Punt CJ
Invest New Drugs; 2008 Aug; 26(4):393-7. PubMed ID: 18335169
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab-related surgical site complication despite primary tumor resection in colorectal cancer patients.
Bège T; Lelong B; Viret F; Turrini O; Guiramand J; Topart D; Moureau-Zabotto L; Giovannini M; Gonçalves A; Delpero JR
Ann Surg Oncol; 2009 Apr; 16(4):856-60. PubMed ID: 19156464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
